Anemia Not A “Deal Breaker” For Boceprevir – SPRINT-1 Study Investigator
Higher rate of anemia seen with HCV patients treated with boceprevir versus control is manageable, Schering maintains.
Higher rate of anemia seen with HCV patients treated with boceprevir versus control is manageable, Schering maintains.